Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

PAVmed (PAVM) Gains from Investment Securities (2021 - 2025)

PAVmed (PAVM) has 5 years of Gains from Investment Securities data on record, last reported at $5000.0 in Q3 2025.

  • For Q3 2025, Gains from Investment Securities changed N/A year-over-year to $5000.0; the TTM value through Sep 2025 reached $2000.0, changed N/A, while the annual FY2024 figure was $1.1 million, 80.65% down from the prior year.
  • Gains from Investment Securities reached $5000.0 in Q3 2025 per PAVM's latest filing, down from $2.5 million in the prior quarter.
  • Across five years, Gains from Investment Securities topped out at $2.6 billion in Q3 2021 and bottomed at -$3000.0 in Q2 2024.
  • Average Gains from Investment Securities over 5 years is $145.7 million, with a median of $28500.0 recorded in 2022.
  • Peak YoY movement for Gains from Investment Securities: plummeted 102.65% in 2024, then skyrocketed 83433.33% in 2025.
  • A 5-year view of Gains from Investment Securities shows it stood at $1.4 million in 2021, then tumbled by 98.94% to $15000.0 in 2022, then tumbled by 73.33% to $4000.0 in 2023, then surged by 26532.98% to $1.1 million in 2024, then plummeted by 99.53% to $5000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Gains from Investment Securities were $5000.0 in Q3 2025, $2.5 million in Q2 2025, and $2000.0 in Q1 2025.